The reiteration of a Buy rating and maintenance of an $11 price target by a reputable analyst like Ed Arce could positively influence investor sentiment towards Galectin Therapeutics. This endorsement reaffirms the company's potential in the eyes of investors, likely leading to a positive short-term impact on the stock price.